Literature DB >> 26944294

Three challenges described for identifying participants with missing data in trials reports, and potential solutions suggested to systematic reviewers.

Elie A Akl1, Lara A Kahale2, Shanil Ebrahim3, Pablo Alonso-Coello4, Holger J Schünemann5, Gordon H Guyatt5.   

Abstract

OBJECTIVE: To categorize the challenges in determining the extent of missing participant data in randomized trials and suggest potential solutions for systematic review authors. STUDY DESIGN AND
SETTING: During the process of updating a series of Cochrane systematic reviews on the topic of anticoagulation in patients with cancer, we identified challenges and used an iterative approach to improve, and a consensus process to agree on the challenges identified, and to suggest potential ways of dealing with them. The five systematic reviews included 58 trials and 75 meta-analyses for patient-important dichotomous outcomes with 27,037 randomized participants.
RESULTS: We identified three categories of challenges: (1) Although systematic reviewers require information about missing data to be reported by outcome, trialists typically report the information by participant; (2) It is not always clear whether the trialists followed up participants in certain categories (e.g., noncompliers), that is, whether some categories of participants did or did not have missing data; (3) It is not always clear how the trialists dealt with missing data in their analysis (e.g., exclusion from the denominator vs. assumptions made for the numerator). We discuss potential solutions for each one of these challenges and suggest further research work.
CONCLUSION: Current reporting of missing data is often not explicit and transparent, and although our potential solutions to problems of suboptimal reporting may be helpful, reliable and valid characterization of the extent and nature of missing data remains elusive. Reporting of missing data in trials needs further improvement.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Attrition bias; Lost to follow-up; Missing participant data; Non-compliance; Randomized controlled trials; Systematic reviews

Mesh:

Substances:

Year:  2016        PMID: 26944294     DOI: 10.1016/j.jclinepi.2016.02.022

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  13 in total

Review 1.  Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.

Authors:  Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Charbel F Matar; Maddalena Barba; Victor E D Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2017-12-29

Review 2.  Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.

Authors:  Lara A Kahale; Charbel F Matar; Ibrahim Tsolakian; Maram B Hakoum; Maddalena Barba; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2021-10-08

Review 3.  Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.

Authors:  Lara A Kahale; Charbel F Matar; Ibrahim Tsolakian; Maram B Hakoum; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Lisa K Hicks; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2021-09-28

Review 4.  Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.

Authors:  Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Charbel F Matar; Irene Terrenato; Francesca Sperati; Maddalena Barba; Victor Ed Yosuico; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2018-06-19

Review 5.  Anticoagulation for people with cancer and central venous catheters.

Authors:  Lara A Kahale; Ibrahim G Tsolakian; Maram B Hakoum; Charbel F Matar; Maddalena Barba; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2018-06-01

Review 6.  Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.

Authors:  Maram B Hakoum; Lara A Kahale; Ibrahim G Tsolakian; Charbel F Matar; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2018-01-24

Review 7.  Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.

Authors:  Lara A Kahale; Charbel F Matar; Maram B Hakoum; Ibrahim G Tsolakian; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2021-12-08

Review 8.  Parenteral anticoagulation in ambulatory patients with cancer.

Authors:  Elie A Akl; Lara A Kahale; Maram B Hakoum; Charbel F Matar; Francesca Sperati; Maddalena Barba; Victor E D Yosuico; Irene Terrenato; Anneliese Synnot; Holger Schünemann
Journal:  Cochrane Database Syst Rev       Date:  2017-09-11

Review 9.  Anticoagulation for perioperative thromboprophylaxis in people with cancer.

Authors:  Charbel F Matar; Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Itziar Etxeandia-Ikobaltzeta; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2018-07-11

10.  A systematic survey shows that reporting and handling of missing outcome data in networks of interventions is poor.

Authors:  Loukia M Spineli; Juan J Yepes-Nuñez; Holger J Schünemann
Journal:  BMC Med Res Methodol       Date:  2018-10-24       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.